EUVIMEDEUVIMED entdecken
Multizentrische StudieBeobachtungsstudieOpen Access · CC BY 4.0

European Unmet Needs in the Management of Neovascular Age-Related Macular Degeneration in Daily Practice

Clotilde Boudousq, Vuong Nguyen, Adrian Hunt, Mark Gillies, Javier Zarranz-Ventura, Louise O'Toole, Els Mangelschots, Pavol Kusenda, Ursula Schmidt-Erfurdt, Andreas Pollreisz, Wajiha Jurdi Kheir, Carolina Arruabarrena und 4 weitere

Ophthalmology Retina · 2024

DOI: 10.1016/j.oret.2024.01.004 ↗

Kurz gefasst

Multizentrische Studie in der Zeitschrift Ophthalmology Retina, 2024. Verfasst von Clotilde Boudousq und 15 weiteren Autor:innen. Beteiligte Einrichtung: Department of Ophthalmology, Dijon University Hospital, Dijon, France. Hauptthemen laut MEDLINE: Registries, Angiogenesis Inhibitors, Intravitreal Injections, Visual Acuity. Die Arbeit wurde bisher 24-mal zitiert (Crossref) und nennt 36 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0). Gefördert von: Macular Disease Foundation Australia, Bayer, Novartis.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

PURPOSE: To evaluate the proportion, predictors, and outcomes of patients with neovascular age-related macular degeneration (nAMD) treated with a high burden of VEGF inhibitor intravitreal (IVT) injections after 2 years in routine clinical practice. DESIGN: Retrospective analysis of data from a prospectively designed observational outcomes registry, the Fight Retinal Blindness! Project, of patients treated in European centers. PARTICIPANTS: Treatment-naïve eyes (1 eye per patient) starting VEGF inhibitors for nAMD from January 2017 to March 2020 with 24 months of follow-up. We analyzed the following 3 treatment-burden groups defined by the mean interval of the 3 closest injections to the 24-month visit: (1) those with a high-treatment burden had injection intervals ≤ 42 days, (2) those with a low-treatment burden had injection intervals between 43 and 83 days; and (3) those with tolerable treatment burden had injection intervals between 84 and 365 days. METHODS: Multinomial regression was used to evaluate baseline risk predictors of patients requiring a high-treatment burden. MAIN OUTCOME MEASURES: The proportion of patients that experienced a high-treatment burden at 2 years and its predictors. RESULTS: We identified 2038 eligible patients completing 2 years of treatment (2038/3943 patients [60%]) with a median (quartile 1, quartile 3) of 13 (10, 17) injections. The proportion of patients with a high-treatment burden was 25% (516 patients) at 2 years. Younger patients (odds ratio [OR], 0.97; 95% confidence interval [CI], 0.96-0.99; P < 0.01) were more likely to have high-treatment burden, whereas eyes with type 3 choroidal neovascular lesions at baseline were significantly less likely (OR, 0.26; 95% CI, 0.13-0.52; P < 0.01). Regarding type of fluid, patients with subretinal fluid only at baseline (OR, 3.85; 95% CI, 1.34-11.01; P = 0.01) and persistent active intraretinal (OR, 1.56; 95% CI, 1.18-2.06; P < 0.01) or subretinal fluid only (OR, 2.21; 95% CI, 1.52-3.21; P < 0.01) after the loading phase had a higher risk of high treatment burden at 2 years. CONCLUSIONS: High treatment burden is a common issue in routine clinical practice in Europe, with a quarter of patients requiring injections of conventional VEGF inhibitors every 6 weeks at 2 years and 40% discontinuing treatment within 2 years. FINANCIAL DISCLOSURE(S): Proprietary or commercial disclosure may be found in the Footnotes and Disclosures at the end of this article.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

RegistriesAngiogenesis InhibitorsIntravitreal InjectionsVisual AcuityTomography, Optical CoherenceVascular Endothelial Growth Factor AWet Macular DegenerationHumansMaleFemaleRetrospective StudiesAgedEuropeFollow-Up StudiesRanibizumabAged, 80 and overBevacizumabReceptors, Vascular Endothelial Growth FactorBlindnessTreatment Outcome

Stichwörter der Autor:innen

Age-related macular degenerationAnti-VEGFRoutine clinical practiceTreatment burdenUnmet need

Substanzen

Angiogenesis InhibitorsVascular Endothelial Growth Factor ARanibizumabBevacizumabReceptors, Vascular Endothelial Growth Factor

Autor:innen und Institutionen

  • Department of Ophthalmology, Dijon University Hospital, Dijon, France.
  • The University of Sydney, Sydney Medical School, Discipline of Ophthalmology, Save Sight Institute, Sydney, New South Wales, Australia.
  • Hospital Clinic de Barcelona, Universitat de Barcelona, Institut de Investigacions Biomediques August Pi i Sunyer (IDIBAPS), Barcelona, Spain.
  • Department of Ophthalmology, Mater Private Network, Dublin, University College Dublin, Ireland.
  • Oogartsenpraktijk Alken, Alken, Belgium.
  • Department of Ophthalmology, University Hospital - St. Michael's Hospital, Bratislava, Slovakia.

Förderung

  • Macular Disease Foundation Australia
  • Bayer
  • Novartis

Zitieren

APA

Boudousq, C., Nguyen, V., Hunt, A., Gillies, M., Zarranz-Ventura, J., O'Toole, L., Mangelschots, E., Kusenda, P., Schmidt-Erfurdt, U., Pollreisz, A., Kheir, W. J., Arruabarrena, C., Vujosevic, S., Barthelmes, D., Creuzot-Garcher, C., & Gabrielle, P. H. (2024). European Unmet Needs in the Management of Neovascular Age-Related Macular Degeneration in Daily Practice. Ophthalmology Retina. https://doi.org/10.1016/j.oret.2024.01.004

Vancouver

Boudousq C, Nguyen V, Hunt A, Gillies M, Zarranz-Ventura J, O'Toole L, et al. European Unmet Needs in the Management of Neovascular Age-Related Macular Degeneration in Daily Practice. Ophthalmology Retina. 2024. doi:10.1016/j.oret.2024.01.004

BibTeX
@article{Boudousq2024,
  author = {Boudousq, Clotilde and Nguyen, Vuong and Hunt, Adrian and Gillies, Mark and Zarranz-Ventura, Javier and O'Toole, Louise and Mangelschots, Els and Kusenda, Pavol and Schmidt-Erfurdt, Ursula and Pollreisz, Andreas and Kheir, Wajiha Jurdi and Arruabarrena, Carolina and Vujosevic, Stela and Barthelmes, Daniel and Creuzot-Garcher, Catherine and Gabrielle, Pierre-Henry},
  title = {European Unmet Needs in the Management of Neovascular Age-Related Macular Degeneration in Daily Practice},
  journal = {Ophthalmology Retina},
  year = {2024},
  doi = {10.1016/j.oret.2024.01.004}
}
Kostenlos starten →